GLP1-RAs attenuate the inflammation in MASLD by downregulating multiple inflammatory factors In animal models, GLP-1RAs have shown promising results in decreasing the expression of various inflammatory markers, including TLR2 and C-X3-C chemokine receptor 1 (CX3CR1), as well as reducing the expression of genes related to liver fibrosis and fat accumulation
In experimental models, suppression of spermatogenesis in the testes and degeneration of primordial follicles and granulosa cells in the ovaries are considered hallmark features of platinum-induced gonadotoxicity.8 Chemotherapeutic agents have been shown to deplete intracellular Glutathione (GSH), one of the major endogenous antioxidants, while simultaneously increasing Myeloperoxidase (MPO) activity, an indicator of inflammatory response, and elevating Malondialdehyde (MDA), a marker of lipid peroxidation.9 Co-administration of antioxidants during chemotherapy has therefore been proposed as a strategy to mitigate oxidative stress-induced tissue injury and improve therapeutic tolerance
Published research has explored its effects on stimulating collagen types I and III, elastin production, and skin elasticity
The results highlight that GLP-1 RA treatment was consistently linked to reductions in PASI scores and, in most cases, improvements in DLQI
